# Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma

> **NCT00002892** · PHASE3 · COMPLETED · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 1000 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa

## Key facts

- **NCT ID:** NCT00002892
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-10
- **Primary completion:** —
- **Final completion:** 2001-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002892, "Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*